Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

LAWSUIT FILED: bluebird bio, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

BLUE

BOSTON, March 18, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, reminds investors that a lawsuit for violation of the federal securities laws has been filed against bluebird bio, Inc. (NASDAQ: BLUE) and certain of its executives.

One of bluebird’s gene therapy programs is called LentiGlobin, and is in design to treat sickle cell disease. On May 11, 2020, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application (“BLA”) to the U.S. Food and Drug Administration for its product, LentiGlobin, in the second half of 2021. In making this announcement, bluebird stated that it had “general agreement with [the] FDA” as to the requirements of the clinical data package required to support the BLA, and that “all operational plans . . . reflect COVID-19 uncertainties and recent program shifts.”

However, on November 4, 2020, bluebird disclosed that it would no longer file the BLA for LentiGlobin in the second half of 2021 as expected. Instead, citing “feedback” from the FDA requiring the Company to provide additional data, along with “COVID-19 related shifts and contract manufacturing organization COVID-19 impacts,” bluebird said it would not submit the BLA until late 2022. The market was stunned by this development, and shares fell by nearly 17% to close at just $48.83 on November 5, 2020.

A lawsuit has been filed against bluebird and certain of its executives in the U.S. District Court for the Eastern District of New York. The lawsuit is captioned Leung v. bluebird, Inc., et al. , No. 21-cv-00777 (E.D.N.Y.). The suit alleges that bluebird misled investors as to the timing and likelihood of success of its plans to submit a BLA to the FDA for LentiGlobin by the second half of 2021.

If you purchased or acquired shares of bluebird between May 11, 2020 and November 4, 2020, you are strongly encouraged to contact the nationally-recognized securities law firm Block & Leviton LLP ( www.blockleviton.com ), at (617) 398-5600, via email at cases@blockleviton.com , or visit our website for information on the case. The deadline to move the Court to be appointed lead plaintiff is April 13, 2021.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
SOURCE: Block & Leviton LLP
www.blockleviton.com


Primary Logo